{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-039705","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.318120+00:00","generated_at":"2026-05-17T01:41:27.215146+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BridgeBio reports positive Phase 3 results for encaleret in ADH1; 76% met primary endpoint","bullets":["76% of encaleret-treated patients achieved both serum and urine calcium targets vs 4% on conventional therapy (p<0.0001).","91% on encaleret achieved intact PTH above lower limit vs 7% on conventional therapy (p<0.0001).","Encaleret was well-tolerated with no discontinuations related to study drug.","NDA submission to FDA planned H1 2026; EMA submission to follow.","BridgeBio plans to initiate registrational trials in pediatric ADH1 and chronic hypoparathyroidism in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-039705","json":"https://secwatch.observer/filing/0001140361-25-039705.json","markdown":"https://secwatch.observer/filing/0001140361-25-039705.md","text":"https://secwatch.observer/filing/0001140361-25-039705.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000114036125039705/0001140361-25-039705-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000114036125039705/ef20057894_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:41:27.215146+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}